Researchers at the University of Birmingham say they've identified a promising way to dial down brain inflammation tied to Alzheimer's disease, Parkinson's disease and traumatic brain injury — by blocking a single receptor on immune cells inside the brain.
The team, led by Nicholas Barnes, a professor of neuropharmacology at Birmingham, studied live cultures of human brain cells and slices of brain tissue obtained during neurosurgery, work the university describes as the first of its kind to use human — rather than animal — brain tissue to study the mechanism. The findings were published Oct. 5 in the journal Brain.
The receptor in question, P2X7, sits on microglia — the brain's resident immune cells — and drives the release of cytokines, inflammatory proteins that can damage surrounding neurons when microglia become chronically overactive, as they do in several neurodegenerative diseases. Because isolated human microglia quickly lose their defining traits outside the brain, the researchers instead converted blood-derived monocytes into microglia-like cells to study how they behave as they're damaged. Blocking P2X7 with a targeted antagonist significantly reduced the inflammatory signals released by both the brain tissue slices and the lab-grown immune cells.
Barnes called the result a step toward "repurposing existing therapeutics to combat neuroinflammation at its source," noting that several P2X7-blocking compounds have already been through earlier-stage clinical testing for other conditions — a head start, in principle, over developing an entirely new drug. He said the next step is designing clinical trials in patients with neurodegenerative conditions and traumatic brain injury.
Still a Preclinical Finding
That step hasn't yet been taken. The Birmingham findings, while novel in their use of human tissue, remain preclinical: no patient has been treated, and the monocyte-derived cells used in the lab are a stand-in for real brain microglia, not the cells themselves. Outside researchers have separately noted that past P2X7-targeted compounds have struggled with insufficient selectivity and poor penetration across the blood-brain barrier — two practical hurdles that would need to be solved before any repurposed drug could reach patients. The university's own announcement frames Alzheimer's, Parkinson's, multiple sclerosis, depression and schizophrenia as possible future applications — forward-looking possibilities, not results the study itself demonstrated.
Still, the receptor has drawn sustained scientific interest: review literature on P2X7 describes a growing case for its role in neurodegeneration, built up over more than a decade of laboratory and animal work. Barnes's team says the Birmingham data mark one of the more direct human-tissue demonstrations yet, in a field researchers argue has moved slowly given the receptor's complexity.